top of page

Amylyx Pharmaceuticals LUCIDITY trial met its prespecified primary endpoint

48 minutes ago
2 min read

Amylyx Pharmaceuticals has presented results from the 16-week double-blind treatment period of the Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, in participants with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) surgery, at the ObesityWeek 2026 Annual Meeting.


LUCIDITY met its prespecified primary endpoint, demonstrating a 55% reduction in the composite rate of self-monitoring of blood glucose (SMBG)-confirmed Level 2 and blinded Event Adjudication Committee (EAC)-adjudicated Level 3 hypoglycaemic events compared with placebo (Least squares mean event rate of 0.55 events per week in avexitide arm compared to 1.24 events per week in placebo arm, p=0.0000034).


LUCIDITY also met all prespecified, multiplicity-controlled secondary event-rate endpoints, reducing SMBG-confirmed Level 2 hypoglycaemic events by 63% (p=0.0000032), EAC-adjudicated Level 3 hypoglycaemic events by 47% (p=0.0016), and continuous glucose monitoring (CGM)-detected Level 2 hypoglycaemic events by 42% (p=0.00016) compared with placebo. In a secondary analysis that evaluated change from baseline within each arm, events decreased by 72.9% in the avexitide arm and by 37.8% in the placebo arm (p=0.000034 for the between-arm difference).


Avexitide was generally well tolerated, with a safety profile consistent with that observed across prior PBH clinical trials. Treatment-emergent adverse events were primarily gastrointestinal and injection-site related and were generally mild to moderate in intensity. There were no deaths and no treatment-related serious adverse events. No clinically meaningful changes in body weight or fasting plasma glucose were observed during the 16-week double-blind treatment period.


“PBH is a chronic metabolic condition characterized by recurrent hypoglycemia. Each a event carries the potential for serious acute consequences and the cumulative burden of living with recurrent and unpredictable events can significantly affect daily functioning, independence, health and quality of life,” said Dr Marilyn Tan, Principal Investigator of the LUCIDITY clinical trial and Clinical Professor at the Stanford School of Medicine. “The debilitating nature of this condition is clear when you look at the participants of LUCIDITY. At baseline, the majority of participants entered the study experiencing daily hypoglycemia symptoms, with many reporting a history of loss of consciousness and hypoglycemia-related hospitalizations. This substantial disease burden makes the consistent reductions in hypoglycaemic events seen with avexitide compelling.”


LUCIDITY is a multicentre, randomised, double-blind, placebo-controlled Phase 3 clinical trial that enrolled 78 adults with PBH following RYBG surgery. After a 3-week run-in, participants were randomized 3:2 to avexitide 90mg subcutaneously once daily or placebo. Participants received standard-of-care dietary management for PBH throughout the run-in and 16-week double-blind treatment period. More than 90% of participants completed the double-blind treatment period, including 45/47 participants randomized to avexitide and 28/31 randomized to placebo.


All eligible participants entered the 32-week open-label extension period. Baseline demographic and disease characteristics were generally balanced between groups. Participants in LUCIDITY had substantial disease burden at baseline: 68% reported daily hypoglycaemic symptoms, 47% had a history of loss of consciousness and 28% had a history of hypoglycemia-related hospitalizations.

The FDA previously granted avexitide Breakthrough Therapy Designation for PBH. LUCIDITY’s 32-week open label extension period and the avexitide Expanded Access Program for eligible adults with PBH following RYGB surgery remain ongoing.

Comments


Weekly Digest

Get a round-up of the main headlines from Bariatric News, directly to your inbox each week.

Get in touch!
Email: info@bariatricnews.net

©2026 Dendrite Clinical Systems Ltd. All rights reserved.
No part of this website may be reproduced, stored in a retrieval system, transmitted in any form or by any other means without prior written permission from the Managing Editor. The views, comments and opinions expressed within are not necessarily those of Dendrite Clinical Systems or the Editorial Board. Bariatricnews.net is a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

bottom of page